2014
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Medicine 2014, 3: 293-299. PMID: 24464780, PMCID: PMC3987079, DOI: 10.1002/cam4.164.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerPathological complete responsePositive breast cancerBreast cancerPreoperative capecitabineClinical responseHER2-negative operable breast cancerDihydropyrimidine dehydrogenaseOnly grade 3 toxicityOverall clinical response rateThymidine phosphorylaseGrade 3 responsePartial clinical responsePathological response assessmentsPreoperative chemotherapy regimensClinical response rateComplete clinical responseGrade 3 toxicityOperable breast cancerPhase II studyPalmar-plantar erythrodysesthesiaMetastatic breast cancerTime of surgeryMiller-Payne
2012
Aromatase Inhibition in Obese Women: How Much Is Enough?
Ligibel JA, Winer EP. Aromatase Inhibition in Obese Women: How Much Is Enough? Journal Of Clinical Oncology 2012, 30: 2940-2942. PMID: 22802318, DOI: 10.1200/jco.2012.43.7244.Peer-Reviewed Original Research
2011
Adjuvant chemotherapy in luminal breast cancers
Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers. The Breast 2011, 20: s128-s131. PMID: 22015279, DOI: 10.1016/s0960-9776(11)70309-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Agents, HormonalBiomarkersBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsAdjuvant endocrine therapyLuminal breast cancerEndocrine therapyBreast cancerEstrogen receptorAdjuvant chemotherapyProgesterone receptorHER2-negative breast cancerER-positive breast tumorsAddition of chemotherapyER-positive diseaseER-positive tumorsUse of chemotherapySubset of patientsSubgroup of patientsER-negative tumorsAdditional therapyCytotoxic chemotherapyEndocrine sensitivityClinicians' estimationTherapeutic responseFavorable outcomeCurrent biomarkersChemotherapyBreast tumors
2009
Breast cancer. Clinical practice guidelines in oncology.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2009, 7: 122-92. PMID: 19200416, DOI: 10.6004/jnccn.2009.0012.Peer-Reviewed Original ResearchAlgorithmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAromatase InhibitorsBreastBreast NeoplasmsCombined Modality TherapyFemaleHumansLymphatic MetastasisMastectomyNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Hormone-DependentPostmenopausePremenopauseRandomized Controlled Trials as TopicReceptor, ErbB-2Selective Estrogen Receptor ModulatorsSentinel Lymph Node BiopsyTamoxifenTrastuzumab
2008
Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. Journal Of The National Cancer Institute 2008, 100: 642-648. PMID: 18445827, PMCID: PMC2864146, DOI: 10.1093/jnci/djn100.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCytochrome P-450 CYP2D6Decision Support TechniquesDisease-Free SurvivalEstrogen Receptor ModulatorsFemaleGenotypeHumansMarkov ChainsMiddle AgedMutationNeoplasms, Hormone-DependentOdds RatioPostmenopauseReceptors, EstrogenSelective Estrogen Receptor ModulatorsTamoxifenConceptsDisease-free survivalWt/wt patientsAromatase inhibitorsBreast cancerCYP2D6 genotypeEndocrine therapyWT patientsNorth Central Cancer Treatment Group trialsEstrogen receptor-positive breast cancerBreast International Group (BIG) 1Optimal adjuvant endocrine therapyReceptor-positive breast cancerDisease-free survival outcomesAromatase inhibitor monotherapyAdjuvant endocrine therapyAdjuvant endocrine treatmentPostmenopausal breast cancerActive tamoxifen metabolitesBreast cancer patientsCytochrome P450 2D6Adjuvant tamoxifenEndocrine treatmentPostmenopausal womenHazard ratioInhibitor monotherapyEndocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference
Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference. Cancer 2008, 112: 673-678. PMID: 18072254, DOI: 10.1002/cncr.23194.Peer-Reviewed Original ResearchConceptsEarly breast cancerBreast cancerEndocrine therapyEndocrine agentsPreclinical modelsBreast cancer prevention effortsCancer prevention effortsEndocrine treatmentOngoing trialsTumor responseKey trialsMultidisciplinary meetingValuable followPatient carePatient treatmentTherapyCancerPrevention effortsReview of dataPatientsTreatmentRecent dataConference proceedingsTrialsEndocrine
2006
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement. Clinical Cancer Research 2006, 12: 997s-1000s. PMID: 16467115, DOI: 10.1158/1078-0432.ccr-05-2268.Peer-Reviewed Original Research
2004
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal Of Medicine 2004, 351: 971-977. PMID: 15342805, DOI: 10.1056/nejmoa040587.Peer-Reviewed Original ResearchConceptsWomen 70 yearsEarly breast cancerBreast cancerOverall survivalRegional recurrenceDistant metastasisRadiation therapyEstrogen receptor-positive breast carcinomasFrequency of mastectomyClinical stage IPrimary end pointFive-year ratesRate of mastectomyPositive breast cancerYears of ageSignificant differencesAdjuvant therapyAdverse eventsSpecific survivalLocal recurrenceCosmetic resultsOnly significant differenceBreast carcinomaLumpectomyStage I
2003
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research 2003, 9: 443s-6s. PMID: 12538498.Peer-Reviewed Original ResearchAntineoplastic Agents, HormonalBreast NeoplasmsDrug Resistance, NeoplasmFemaleForecastingHumansNeoplasms, Hormone-Dependent